Patents Represented by Attorney Johanna M. Corbin

Find this attorney in the Justia Lawyer Directory

  • Substituted thiazoles
    Patent number: 7541475
    Abstract: This invention is directed to processes for making substituted thiazoles. The substituted thiazole, ethyl 2-(4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate, also known as TEI-6720, is useful for treatment of gout and hyperuricemia. This compound belongs to a class of substituted thiazoles that inhibit xanthine oxidase and thus block uric acid production.
    Type: Grant
    Filed: July 30, 2004
    Date of Patent: June 2, 2009
    Assignee: Abbott Laboratories
    Inventors: Timothy A. Robbins, Helen Zhu, Jun Shao
  • Method for the preparation of fluticasone and related 17?-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods
    Patent number: 7214807
    Abstract: This invention discloses a novel method for the conversion of carboxylic acids to carbothioic acids and application of the method to the preparation of androstane carbothiolates, such as fluticasone propionate, which avoids column chromatography.
    Type: Grant
    Filed: May 18, 2004
    Date of Patent: May 8, 2007
    Assignee: Abbott Laboratories
    Inventors: Jufang Barkalow, Steven A. Chamberlin, Arthur J. Cooper, Azad Hossain, John J. Hufnagel, Denton Langridge
  • Farnesyltransferase inhibitors
    Patent number: 7211595
    Abstract: Substituted imidazoles and thiazoles having the formula are useful for inhibiting farnesyltransferase. Also disclosed are farnesyltransferase-inhibiting compositions and methods of inhibiting farnesyltransferase in a patient.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: May 1, 2007
    Assignee: Abbott Laboratories
    Inventors: Akiyo K. Claiborne, Stephen L. Gwaltney, II, Lisa A. Hasvold, Qun Li, Tongmei Li, Nan-Horng Lin, Robert A. Mantei, Todd W. Rockway, Hing L. Sham, Gerard M. Sullivan, Yunsong Tong, Gary Wang, Le Wang, Xilu Wang, Wei-Bo Wang
  • Protein-tyrosine phosphatase inhibitors and uses thereof
    Patent number: 7169797
    Abstract: The present invention is directed to compounds of formula (I), or a pharmaceutically suitable salt or prodrug thereof, which are useful for the selective inhibition of protein tyrosine phosphatase-1B (PTP1B), and are useful for the treatment of disorders caused by overexpressed or altered protein tyrosine phosphatase 1B.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: January 30, 2007
    Assignee: Abbott Laboratories
    Inventors: Zhili Xin, Gang Liu, Zhonghua Pei, Bruce G. Szczepankiewicz, Michael D. Serby, Hongyu Zhao
  • Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
    Patent number: 7169888
    Abstract: Compounds of formula (SEQ ID NO:2) and (SEQ ID NO:3), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: January 30, 2007
    Assignee: Abbott Laboratories
    Inventors: Fortuna Haviv, Michael F. Bradley
  • Macrocyclic kinase inhibitors
    Patent number: 7163939
    Abstract: Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: November 3, 2004
    Date of Patent: January 16, 2007
    Assignee: Abbott Laboratories
    Inventors: Nan-Horng Lin, Gaoquan Li, Magdalena K. Przytulinska, Thomas J. Sowin, Gerard M. Sullivan, Zhi-Fu Tao, Yunsong Tong, Le Wang
  • Hexa-, hepta-, and octapeptides having antiangiogenic activity
    Patent number: 7122625
    Abstract: Compounds of formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: October 17, 2006
    Assignee: Abbott Laboratories
    Inventors: Fortuna Haviv, Michael F. Bradley
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Patent number: 7071182
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: July 4, 2006
    Assignee: Abbott Laboratories
    Inventors: Andrew J. Souers, Christine A. Collins, Ju Gao, Andrew S. Judd, Philip R. Kym, Mathew M. Mulhern, Hing L. Sham, Dariusz Wodka
  • Hepta-, Octa-and nonapeptides having antiangiogenic activity
    Patent number: 7067490
    Abstract: Compounds of formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: June 27, 2006
    Assignee: Abbott Laboratories
    Inventors: Fortuna Haviv, Michael F. Bradley
  • Urea kinase inhibitors
    Patent number: 7056925
    Abstract: Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: June 6, 2006
    Assignee: Abbott Laboratories
    Inventors: Gaoquan Li, Qun Li, Tongmei Li, Nan-Horng Lin, Robert A. Mantei, Hing L. Sham, Gary T. Wang
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Patent number: 7049307
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: May 23, 2006
    Assignee: Abbott Laboratories
    Inventors: Andrew J. Souers, Christine A. Collins, Ju Gao, Andrew S. Judd, Philip R. Kym, Mathew M. Mulhern, Hing L. Sham, Dariusz Wodka
  • TRI-, TETRA-, and penta-peptides having antiangiogenic activity
    Patent number: 7037897
    Abstract: Compounds of formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: May 2, 2006
    Assignee: Abbott Laboratories
    Inventors: Fortuna Haviv, Michael F. Bradley
  • Di-, tri-, and tetra-peptides having antiangiogenic activity
    Patent number: 7001984
    Abstract: Compounds having the formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: February 21, 2006
    Assignee: Abbott Laboratories
    Inventors: Fortuna Haviv, Michael F. Bradley
  • 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
    Patent number: 6989392
    Abstract: The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, which antagonize the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor and are useful for the prevention or treatment of eating disorders, weight gain and obesity.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: January 24, 2006
    Assignee: Abbott Laboratories
    Inventors: Christine A. Collins, Ju Gao, Philip R. Kym, Jared C. Lewis, Andrew J. Souers, Anil Vasudevan, Dariusz Wodka
  • Selective protein tyrosine phosphatatase inhibitors
    Patent number: 6972340
    Abstract: Compounds of formula (I) or therapeutically acceptable salts thereof, are selective protein tyrosine kinase-B (PTP1B) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of disorders using the compounds are disclosed.
    Type: Grant
    Filed: August 29, 2001
    Date of Patent: December 6, 2005
    Assignee: Abbott Laboratories
    Inventors: Gang Liu, Bruce G. Szczepankiewicz, Zhonghua Pei, Zhili Xin, David A. Janowick
  • Antagonists of melanin concentrating hormone receptor
    Patent number: 6921821
    Abstract: This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1). The compounds are represented by formula I: where m is zero or one, n is zero to two, Y is oxygen or —N(R9)—, R1, R2, R3, R4, R5, R9 and Ring A are defined in the specification. Coumarin and quinolone compounds where R1 and R2 together form a fused benzo ring are preferred. The invention also provides compounds of formula VI where the coumarin moiety is replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related disorders, particularly overweight conditions including obesity.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: July 26, 2005
    Assignee: Abbott Laboratories
    Inventors: Christopher Blackburn, Su-Jen Lai, Jennifer L. Che, Martin P. Maguire, Michael A. Patane, Matthew J. LaMarche, Courtney A. Cullis, James Brown, Anil Vasudevan, Jennifer C. Freeman, Mathew M. Mulhern, John K. Lynch, Ju Gao, Dariusz Wodka, Andrew J. Souers, Rajesh Iyengar, Mary Katherin Verzal, Philip R. Kym
  • Antiangiogenic drug to treat cancer, arthritis and retinopathy
    Patent number: 6849757
    Abstract: Compounds having Formula I or pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting angiogenesis in a mammal.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: February 1, 2005
    Assignee: Abbott Laboratories
    Inventors: Megumi Kawai, Jack Henkin, George S. Sheppard, Richard A. Craig
  • Kinase inhibitors
    Patent number: 6831175
    Abstract: Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: December 14, 2004
    Assignee: Abbott Laboratories
    Inventors: Qun Li, Keith W. Woods, Gui-Dong Zhu, John P. Fischer, Jianchun Gong, Tongmei Li, Virajkumar Gandhi, Sheela A. Thomas, Garrick K. Packard, Xiaohong Song, Jason N. Abrams, Robert B. Diebold, Jürgen Dinges, Charles W. Hutchins, Vincent S. Stoll, Saul H. Rosenberg, Vincent L. Giranda
  • Trisubstituted-N-[(1S)-1,2,3,4-Tetrahydro-1-naphthalenyl]benzamides which inhibit P2X3 and P2X2/3 containing receptors
    Patent number: 6831193
    Abstract: Compounds of formula (I) are novel P2X3 and P2X2/P2X3 antagonists which are useful in treating pain, urinary incontinence and bladder overactivity.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: December 14, 2004
    Assignee: Abbott Laboratories
    Inventors: Chih-Hung Lee, Richard J. Perner, Daniel P. Larson, John R. Koenig, Arthur R. Gomtsyan, Guo Zhu Zheng, Stanley DiDomenico, Andrew O. Stewart, Erol K. Bayburt
  • N-alkylated peptides having antiangiogenic activity
    Patent number: 6777535
    Abstract: N-Alkylated peptides of formula (I) Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11  (I), are useful for inhibiting angiogenesis. Also disclosed are angiogenesis-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.
    Type: Grant
    Filed: October 31, 2000
    Date of Patent: August 17, 2004
    Assignee: Abbott Laboratories
    Inventors: Fortuna Haviv, Jack Henkin, Douglas M. Kalvin, Michael F. Bradley